

Allocas, Inc. Contamination Alert Systems™

2151 Lynnwood Drive
Schenectady, NY 12309

Peter E. Kent, P.E.
(518) 393-3783
pkent@orthobiosystems.com

Management

Peter E. Kent, PE, CEO
Prof. Philip Borer, CEO
OrthoSystems
Prof. Bruce Hudson, VP
OrthoSystems
Dr. Mark McPike, CSO
OrthoSystems

Employees

2 (plus 3 PhDs in
OrthoSystems)

Industry

Environmental sensing
(including military and
homeland defense)

Finance

Financing Sought
\$250K in 2006 plus
\$2M in 2007

Use of Funds

2006: Sale of remote con-
tamination sensors for
water systems including
development of a crypto-
Contamination Alert
System™ (CAS) and
Citywide CAS display
system. 2007: Sales,
assembly and monitoring
groups.

Current Investors

Syracuse Univ.,
Prof. Borer, Prof. Hudson,
Peter Kent

Financing to Date

Competitive OrthoSystems-
Allocas Grants received to date:
1. \$850K NIH SBIRs for HIV Alloswitch
2. \$100K DHS SBIR for ricin Alloswitch
3. \$ 50K NYIEQ grant for crypto Alloswitch
4. \$45K SUNY/SS grant for crypto Alloswitch

Company Description

Allocas is a daughter of the Syracuse University
bio-tech spin-off OrthoSystems, Inc dedicated to
developing the patent pending technology for real-
time contamination detection in water, air and food.

Business Strategy

Except for chlorine levels in the drinking water at
the water treatment plant, almost nothing else is
monitored prior to water consumption by the public.
Current lab methods are too slow. Allocas will detect
contamination being injected anywhere in the water
system by terrorists or vandals or from "old" water.

Product/Service

Real time remote detection of natural environmental
or terrorist induced contamination in city water
systems. Displaying that information as contamina-
tion contours on a city street map so that the
contamination can be isolated and flushed.
Supported by a national monitoring center.

Patents

In addition to the composition-of-mater patent
"antibody" for each contaminate
SU/OrthoSystems/Allocas has six pending
"methods" patents all sub-licensed to Allocas:
1. DSA: Method to rapidly discover the chemical
equivalent of an antibody for any biological target
2. DIREX: second method to discover the chemical
equivalent of an antibody
3. AlloSwitch: Method to detect when the "antibody"
has found its target
4. "X"ium: Method to increase the signal-to noise ratio
by 1000
5. "Tethering": Method to increase selectivity by
10,000
6. Mini-SELEX: Major improvement to the patented
SELEX method

Target Market

Initially the 11,000 public water systems in the USA
who serve over 10,000 customers each. On Dec. 15,
2005 EPA mandated that each detect and treat
cryptosporidium (crypto) in their water. Then Allocas
will target water systems worldwide plus building air
and food processing contamination detection.

Competition

Source Sentinel, LLC, (startup) Syracuse NY and
HACH, Colorado

Bank

OrthoSystems
Key Bank, NA, Allocas same

Auditors

OrthoSystems
Grimaldi & Nelkin, Syracuse
Allocas
PWC

Law Firm

OrthoSystems
Hancock & Estabrook, LLP, Syracuse
Allocas
Hancock & Estabrook, LLP, Syracuse

Competitive OrthoSystems/Allocas Grants
expected by July 30, 2006
1. \$100K NIH SBIR to speed Alloswitches
2. \$ 50K GFG grant for remote monitoring
3. \$ 50K NIH for HIV drug discovery
OrthoSystems/ Allocas Grants expected 1stQ 2007
\$750K NIH SBIR to speed Alloswitches

Financials	Last Year	This Year	Three Years from now
Revenue	\$400K	\$400,000 in R & D grants	\$90M
EBIT	\$0	\$0	\$13M

As It Is, Inc. –Referred to as Ai3

Barid Research Park
1576 Sweet Home Road
Amherst, NY 14228

Bill Koehler
President & CEO
716 308 7311
wdkoehler@asitisinc.com

Management

Jon Ray Hamann, Chair
Bill Koehler, CEO
Jere Northrop, F Partner
Ian C. Gent EVP
Fredrick W. Reed Chief
Technology Officer

Employees

11

Industry

Internet Service Provider
with Artificial Intelligence
Technology

Finance

Financing Sought
\$350K and two \$5-
10Million rounds

Use of Funds

Launch Web Site
Business expansion
Product development

Current Investors

Private Investors
Mill Race Private Equity,
Inc.

Financing to Date

\$6 Million

Company Description

Ai3 founded in 1999, is an Artificial Intelligence research and development company that is commercializing a Web 3.0 subscriber based intelligent website called www.TrueThinker.com that automates and facilitates the discovery, retrieval and organization of information sought by users on the internet.

Business Strategy

Subscribers pay \$2.99 a month or \$24.95 a up front annual payment for an advertising free complete personal web access tool that can be operated from any computer in the world you have secure access to. Sales to be via Viral Marketing plus traditional marketing to consumers and industry players as well as licenses to affinity groups by Corecubed, a renowned virtual marketing company. They have been engaged on a “pay for performance” only approach, to build and retain a 1 million subscriber base. This subscription revenue will be the foundation of our initial revenues while direct to infinity group licensing opportunities will be built to coincide as a compliment to this approach.

Product/Service

TrueThinker solves the problem of search engine disorganization and web information overload. Rather than getting 100 million hits, only a few of which are useful, TrueThinker refines searches, accesses the relevant information, and then provides the user with the data they really wanted, neatly saving both time and money. Once trained by the user, TrueThinker will perceive, intuit, think, value and act on its own.

Technology/Special Expertise

Five patents protect the core Semiotic intellectual property that reads signs and symbols. Ai3 will license the AutoGnome world wide in various applications. 40 years of development now combined with the speed of today's pc processors allows the functionality to be commercialized.

Target Market

With 200 million U.S. Internet users spending 40-76 hours online each month seeking information, TrueThinker has strong market potential. Whether applied to education, recreation, advertising, marketing, financial, and medical or other industries, it enhances and supplies intelligence to any product, thereby improving performance and market dominance...we only need 38,000 subscribers to break even. AOL has 23 million.

Competition

To date, there are few companies that offer true artificial intelligence none with retail accessibility. Google recently announce plans for AI to be ready in 4-5 years.

Bank

HSBC, Buffalo

Accountants

Kane and Able

Law Firm

Phillips Lytle and others

Financials	Last Year	This Year	Three Years from now
Revenue	\$0	\$7,280,000	\$70,700,000
EBIT	\$0	\$1,492,000	\$59,144,000

Axioppe, Inc.

60 Parkhurst Road

518.581.8629
Wilton, NY 12831

Wayne.butler@axioppe.com

Management

Roderick Macneil,
Executive Chairman
Nigel Goddard, CEO
Wayne Butler, VP Business
Development
Anthony Kosky, CTO

Employees

8

Industry

Software & services

Finance

Financing Sought
\$3.5M

Use of Funds

Working capital
Product Development
Building sales team

Current Investors

Private Investors
Business Growth Fund

Financing to Date

\$2.8M

Company Description

Axioppe was founded in 2003. Axioppe's Catalyzer software is the first comprehensive solution to the full range of critical data management needs in biomedical research, including specimen tracking, inventory management, image management, and electronic data capture.

Business Strategy

Axioppe's has confirmed the demand for Catalyzer with sales to high profile publicly funded non profit institutions including the National Cancer Institute and Children's Hospital Boston. Our strategy is to roll Catalyzer out to Pharma, CROs and biotech with upgraded features (due out in version 3.1 in October 2006) which are needed to support regulatory (21 CFR part 11) requirements including audit trail and concurrent access, and other features requested by customers such as web data entry.

Product/Service

Catalyzer is a highly flexible and user configurable, software platform for managing scientific data. It is being used by customers for the four key data management needs in biomedical research, i.e. specimen tracking, inventory management, image management and electronic data capture. Catalyzer is increasingly being purchased by customers to cover all four of these needs, as a comprehensive solution to biomedical data management needs.

Technology/Special Expertise

Axioppe uses a proprietary XML-database together with J2EE web technologies to create a highly flexible and configurable platform for application development. It includes APIs to interface data sources and relational databases. Applications developed on this platform to date target specimen tracking, inventory manage-

ment, image management and electronic data capture. We have already developed a suite of plugins for widely-used scientific formats, giving us an additional significant competitive advantage.

Target Market

The biomedical research industry: Pharma, biotech, CROs, and publicly funded institutions--hospitals, research institutes, and academic institutions--carrying out biomedical research.

Competition

Key competitors in each of the four key applications are: image management (MediaCybernetics); inventory management (Dataworks); electronic data capture (Cambridgesoft); specimen tracking (LabVantage). All of these competitors use relational technology, which does allow them to meet the demand for flexibility and user configurability. Nor can they easily re-engineer their application-specific products to compete against Catalyzer's comprehensive solution.

Bank

NetBank, Atlanta

Auditors

Feely Driscoll, Boston

Law Firm

Foley Hoag, Boston.

Financials	Last Year	This Year	Three Years from now
Revenue	\$42,694	\$400,000	\$9,000,000
EBIT	-\$171,684	-\$410,000	\$4,591,000

Celery, LLC

212 River Street
Troy, NY 12180

Andrew Gibson
518.833.6807
Andrew@mycelery.com

Management

Andrew Gibson, CEO
Neil Grabowsky, VP Sales
Adam Wishneusky, CTO
Ola Mork, Lead Programmer

Employees

4

Industry

Software,
Telecommunications

Finance

Financing Sought

PhsI: \$1MM, Phs II:
\$2MM,
PhsIII: \$9MM

Use of Funds

Marketing
Business expansion
Product(s) Development

Current Investors

Private Investors
Partners

Financing to Date

\$300K

Company Description

Celery, LLC, started in 2004, was founded to create consumer electronics products for the "Late & Never Adopters". Our first product is an email device. We are not an electronics manufacturer; rather, we will "Celeryize" existing products, overlay our positioning tenets and create a profitable service model. Positioning Tenets: 1) keep it simple, 2) keep it affordable & 3) keep the learning curve flat.

Business Strategy

Our business model is to sell our product and service to Seniors initially. We will use both a web and 3rd party channel sales strategy. Celery will be gift-priced as we expect the majority of sales to be to the user's family. We have 3 income streams. Service sales (89% GM), Device Sales (5-10% GM) and a direct cartridge sales program (22% GM). The cartridge program is almost all profit as a third party group will handle most logistics. Eventually, we will sell qualified, value-added advertising ("bring this coupon in to Applebees for a free pie").

Product/Service

The Celery device is an "always on" email platform. Its operation is extremely passive. To receive a message: note and color photos are emailed to our customer's email address. The phone rings, the note and photo are printed out.

To send a message: the customer hand writes a note that is addressed to the email recipient. For example, the customer writes: "Dear Kath" at the top of the note. The note is placed in the device, two quick buttons are pressed and the message is sent.

Technology/Special Expertise

We have filed for both utility and design patents. We developed specialize software that is married with an "off-the-shelf" color fax product. Email messages can be both sent and received by our customers.

Target Market:

There are 71.3mm adults in America who do NOT use email. Our initial target is the Senior market, which makes up half that number.

Competition

Cheap computers, inexpensive email devices and Presto services, which is a new company financed by Kleiner Perkins and Clearview Capital. This group is using an HP photo printer. Their communication is one way. The customer is not allowed to send messages.

Bank

Citizens Bank, Troy, NY.

Auditors

Boykus & Associates, NJ

Law Firm

Schiff, Hardin Associates

Financials	Last Year	This Year	Three Years from now
Revenue	\$0	\$682,000	\$19,460,000
EBIT	\$0	\$(295,000)	\$2,547,000

Change Round-Up, Inc.

1223 Peoples Avenue
Troy, NY 12180

Daniel Quigley
518.276.3949
dquigley@changeroundup.com

Management

Daniel Quigley,
President
Jonathan Falk,
VP Business Development

Employees

3

Industry

Public Relations
Fund Raising

Finance

Financing Sought
\$800,000

Use of Funds

Technology staff
Customer support staff
Marketing
Working capital

Current Investors

Several Private Angels
Owner's Investment

Financing to Date

\$260,000

Company Description

Change Round-Up applies the proven concept of the "Spare Change Jar" to the e-commerce market to help charities raise donations.

E-shoppers are asked at checkout of their favorite retail websites if they would like to "round-up" their total purchase price to the nearest dollar and donate that "spare change" to a charity of their choice. Shoppers are encouraged to designate different (larger) dollar amounts to donate as well.

Business Strategy

While each donation will likely be small, in aggregate donation levels can be tremendous. Change Round-Up charges charities a fee of 10% of donations raised and then pays retailers a fee of 4% of donations to provide an added incentive for their participation.

Retailers also gain the added benefits of improved customer relationships, great PR, and the ability to help great causes with very little investment. (The customers pay donations instead of the retailer, yet the retailer gains the PR benefit associated with being a good corporate citizen)

Product/Service

The Change Round-Up technology is simple to implement and works seamlessly with any e-commerce platform. The CRU Database provides both charities and retailers with real-time donation data and facilitates the collection and disbursement of donations.

Technology/Special Expertise

Change Round-Up has two patents pending. The technology that drives our service has been developed and beta testing is complete.

Target Market

While charities pay our fee, Change Round-Up's real target market is the online retailing industry.

There are thousands of online retailers, yet our primary target is the top 500 online retailers as they control the vast majority of the \$100+ Billion industry. (in fact, the top 100 online retailers account for over half of the online retailing industry, or over 50 billion dollars!)

Change Round-Up has been in discussions with several large online retailers and will likely be launching on a site with significant volume in the near future.

Competition:

Not Applicable.
There are no other companies/organizations utilizing this model.

Bank

National Bank of Coxsackie

Auditors

Sperry, Cuono, Holgate & Churchill, C.P.A.'s,
P.C.

Law Firm

Phillips Lytle, LLP

Financials	Last Year	This Year	Three Years from now
Revenue	\$NA	\$284,134	\$2,722,948
EBIT	\$NA	\$(59,0180)	\$1,698,856

C-Vision, Inc.

105 Jordan Road
Troy NY 12180

Dr. James T. Woo
518-283-7500 x-11
woojt@intersci.com

Management / Management Team

James T. Woo, CEO &
President
Michelle Simkulet,
VP for Operations/IP
Manager
Anne Stuto, Comptroller

Employees

15

Industry

Optical Medical Devices

Financing Sought

\$2,000,000

Use of Funds

Build management team
Build alpha units for
clinical trials
Secure 510(k) approval
Marketing
Production facilitation

Current Investors

InterScience, Inc.

Financing to Date

\$3M government funding,
\$2M ISI IR&D funds

Company Description

C-Vision, Inc. is a start-up being organized by InterScience, Inc., the parent company. C-Vision will target the growing minimally invasive surgery (MIS) market to introduce the C-View endoscope with significantly expanded field of view to advance and expand the use of such procedures that benefits the patient, the provider and realize medical cost savings. C-Vision, Inc. will be incorporated upon the funding event, but continue to be nurtured by InterScience until it becomes self-supporting.

Business Strategy

Initial target market will be for sinuscopy procedures where the need for expanded field of view is the most acute. The company will produce and introduce the product and collaborate with early adopters through medical society meetings and journal publications to gain recognition to expand usage of the C-View endoscope in other MIS procedures to increase valuation, with the expectation that the company will be a very attractive M&A target.

Product/Service

The initial product will be a 4 mm diameter by 7 cm length endoscope primarily for sinuscopy procedures but also used in many other MIS procedures. The design of the endoscope is scalable to any diameter and length, and the product line will gradually expand into other sizes for other procedures.

Technology/Special Expertise

The design of the C-View endoscope is protected by one issued and several pending patents.

Target market

The target market is minimally invasive surgery procedures increasingly being practiced in lieu of conventional surgeries.

Competition

The product will compete in the market place with several established and vertically integrated companies that supplies to the endoscopy market that includes not only endoscopes but also other instruments for performing MIS procedures.

Bank

C-Vision presently operates as an activity within InterScience, Inc, which is the parent company that uses the HSBC as the bank.

Auditors

The books of InterScience, Inc. as the parent company is audited annually by Pryba, Tobin & Company, PC, based in Latham , NY at 40 British American Boulevard.

Law Firm

InterScience, Inc., the parent company is represented by Whiteman, Osterman & Hann for general business; The Yablon Law Firm for patent law, and The Savage Law Firm for entering into business agreements.

Projected Revenues

Revenue-No current revenue, expect revenue at end of 18 months following funding event, \$250K first year, and \$2.5M the year after as breakeven operation.

ENrG Inc.

155 Rano Street, Suite 300
Buffalo, NY 14207

John Olenick
716-390-6740
jolenick@enrg-inc.com

Management

John Olenick, CEO
Venkat Venkateswaran,
VP Technology
Development
William Sunderlin,
Chief Operating Officer
Kathy Olenick,
VP Marketing
James Newkirk,
VP Business
Development

Employees

13

Industry

Energy, Alternative
Energy System
Components, Ceramic
Components

Finance

Financing Sought
\$2M

Use of Funds

Working capital
Business expansion
R&D and Licensing
Marketing

Current Investors

Private Angel Investors
Business Development
Seed Fund
Owners/Principals

Financing to Date

\$519,000

Company Description

ENrG Incorporated was formed in January 2003. ENrG develops and manufactures critical ceramic technologies for clean energy systems, such as fuel cells and gas separation membranes. ENrG's experience in developing and producing SOFC components in areas greatly exceeding industry standards, along with ENrG's prior experience in ceramics, metals, multi-layer ceramic processing puts ENrG in prime position to work with strategic partners through collaborative partnerships and to diversify product offerings in the energy field.

Business Strategy

ENrG's strategy is to leverage private capital with government grant opportunities to achieve large area ceramic technology developments and manufacturing capability leading to commercial clean energy related products. In support of this strategy, ENrG was granted \$1.17MM from NYSERDA and \$3.3 MM from NIST ATP for the development of critical ceramic components for fuel cell and landfill gas purification systems.

Product/Service

SOFC commercialization requires ceramic development and manufacturing capability exceeding the current industry standard surface area of 200 cm². ENrG's experience in developing SOFC components at areas exceeding 400 cm² along with ENrG's prior experience in ceramics, metals, and multi-layer ceramic processing puts ENrG in prime position along with key collaborators to resolve technical issues. ENrG plans to introduce fuel cell components in 2006 and subsequent stack assemblies starting in 2008.

Technology/Special Expertise

SOFC production requires key knowledge in multi-layer ceramic processing, zirconia ceramic material processing, sintering, patterning, electrical testing, handling of large membranes and assemblies. ENrG has a patent disclosure in the area of imbedded sensors for sealing of components into stacks.

Target Market

The DOE forecasts that by 2030 the United States will use 66% more energy than it now uses and produces. Distributed energy generation will play a key role in supplying this additional energy. Leading DEG systems will include wind, solar, microturbines, and fuel cell systems. ENrG customers in the fuel cell segment are expected to include OEMs developing system designs supported by SOFC technology as the power generation component. The SOFC market is forecast to reach \$330 MM by 2007 and multi-billions of dollars beyond 2010.

Competition

The best strategically linked companies or Department of Energy funded are Blasch Precision Ceramics, InDEC recently purchased by H.C. Starck, and Nextech. The SOFC system market is in very early stage development with room for competition and large companies have purchased start-ups for entry into this market.

Bank

M&T Bank, Buffalo, NY

Auditors

Freed Maxick

Law Firm

Harter Secrest & Emery

Financials	Last Year	This Year	Three Years from now
Revenue	\$1,271,858	\$2,200,000	\$14,000,000
EBIT	\$76,902	\$100,000	\$840,000

PhV Corporation.

SUNY Downstate
 Technology Center
 Brooklyn, NY 11203

Aaron Etra
 212. 829. 5565
 917.856.3500
 aaron@etra.com

Management

Aaron Etra, Chairman
 Randy White, CEO
 Elmer Ruckman, President & Chief Technology Officer
 Miroslav Colic, VP Scientific Research
 Peter Fallon, VP Product Development & Applications

Employees

5 (Part Time)

Industry

Health and Beauty Care Products, Biotechnology

Finance

Financing Sought
 \$750,000

Use of Funds

Product Development
 Marketing
 Working Capital

Current Investors

Founders

Financing to Date

\$25M

Company Description

PhV Develops science based efficacious health and beauty care products for a "LOHAS" (Lifestyles of Health And Sustainability) regimen, with potential for prevention and therapy and without generating undesirable effects. The initial products are a suite of liquid PhV Nutri-Solutions™ targeting chronic illnesses and conditions. Future formats will include capsules, tablets, liposomes, creams and gels. PhV's science and proprietary technology supports these initial nutraceutical products as well as future pharmaceuticals.

Business Strategy

PhV's initial alliances have been with the marketing and educational organizations of healthcare practitioners, beginning with compounding pharmacists and expanding to functional (e.g. physicians) or conditions (e.g. diabetes). We will partner with biotech and functional food companies in the second stage, to achieve mass market penetration. Alliances with pharma to produce products complementary to theirs is the third stage. PhV is a leading figure in the International. Conference on Mechanisms of Action of Nutraceuticals (ICMAN) now holding the fourth session.

Product/Service

The first PhV Nutri-Solution™ is being utilized by compounding pharmacists as a cancer therapy adjuvant before, during and after chemo and radiation therapies. Additional such liquid formulations will be developed targeting diabetes-glycemic control, neurodegenerative, cardiovascular, skin and other chronic conditions, ageing and performance problems. Future generations of products will be in pill, tablet, capsule, liposome or other formats and

comprising semi-synthetic and synthetic ingredients in its compounds and colloids. PhV's intellectual property includes two issued patents. One pending and a trademark. PhV has also licensed in technology for nutraceutical applications from a researcher whose Parkinson's drug was just introduced.

Target Market

PhV is initially targeting a U.S. nutraceutical market of 69 billion with \$20 billion being supplements and a global nutraceutical market of \$196 billion with \$63 billion being supplements.

Competition

PhV has an advantage over other existing supplement manufacturers because of its combination of targeted science and alliances with healthcare provider marketing and educational organizations. Other biotech and pharma are viewed by PhV as prospective partners because it's partnering will complement and supplement existing lines.

Bank

Manufactures and Traders Trust Company (M&T)

Auditors

Weiser LLC

Law Firm

ZAG/Sullivan & Worcester

Financials	Last Year	This Year	Three Years from now
Revenue	\$15,000	\$400,000	\$5,184,000
EBIT	\$0	\$0	\$542,000



Pneuma Partners, LLC

1576 Sweet Home Road
Amherst, NY 14222

Edmund A. Egan, MD;
716-636-9096
eeagan@ony.incubator.buffalo.edu

Management

Edmund A. Egan, MD,
CEO, Clinical Trials
William Ferguson,
COO, Manufacturing
Bruce A. Holm, PhD,
Science
James A. Egan, JD,
Business

Employees

5 (unpaid)

Industry

Pharmaceuticals

Finance

Financing Sought
\$15,000,000

Use of Funds

Conduct Phase III
pivotal clinical trials
Prepare clinical
supplement for
FDA approval

Current Investors

The founders

Financing to Date

\$30M on original NDA
\$500K on ARDS
indication

Company Description

Pneuma Partners was created to exploit clinical research demonstrating that Infasurf® (calfactant), a marketed lung surfactant replacement for newborns, is an effective treatment for a subclass of Acute Respiratory Distress Syndrome (ARDS). Pneuma will develop other formulations useful in severe exacerbations of chronic lung disease in adults. The founders rely on their expertise that successfully carried calfactant from research laboratory to approved drug for newborns to create a company that manufactures, sells and develops drugs for severe lung disease.

Business Strategy

Pilot and Phase II clinical data predict that treatment of target patients ARDS lowers the 35% death rate by more than half and diminishes the duration of respiratory failure. Use of the drug will be virtually universal for appropriate patients if the preliminary data is replicated in pivotal trials. There are about 100,000 annual patients with ARDS appropriate for calfactant therapy. All are hospital ICU patients on ventilators. A small specialty sales force will promote the new indication. Profits from ARDS sales will be used to fund future drug(s) development.

Product/Service

Calfactant is a surfactant replacement drug of ONY, Inc., Amherst, NY (which is owned by Dr. Egan, CEO of Pneuma), and manufactured in its FDA approved facility.

Technology/Expertise

Pneuma owned trade secrets and FDA rules eliminate the risk of generic competition. Patent protection and Orphan Drug Designation limit future competition.

Target Market

Most, 75% or more, of these ARDS patients are in ~1,000 large hospitals with multiple ICUs. The remaining 25% are in another ~4,000 smaller hospitals with a single ICU. A sales force of 50 means 20 large and 80 small hospitals per person.

Competition

Two other lung surfactants have potential interest in adult ARDS. Both are European. Curosurf is approved for newborns in the US and Europe and has not been studied in adults. Venticute (Altana) is not approved anywhere and failed in a large trial in adults published in 2004.

Bank

Bank of America
Amherst, NY

Auditors

Semanchin & Wetter
Williamsville, NY

Law Firm

Jackle, Fleischmann & Mugel, Buffalo, NY

Financials	Last Year	This Year	Three Years from now
Revenue	\$0	\$0	\$100M
EBIT	\$0	\$0	\$50M



Polar Industries, Inc.™

214 Mac Arthur Avenue
New Windsor, NY 12553

Geoffrey Anderson
845.569.4818
geoff@polarglobal.com

Management

Syed Zafar, CEO
Geoffrey Anderson, COO
Andrew Raia, Senior Technical
Frank Caputo, VP Sales
JK Gentile, Marketing

Employees

6

Industry

Polar’s world is the \$5 billion Video Surveillance Systems marketplace including cameras recorders and software.

Finance

Financing Sought
\$2.0M

Use of Funds

Working capital
Business expansion
Product manufacturing
Marketing

Current Investors

Management
Aegis Capital
Management

Financing to Date

\$1.2M

Company Description

Polar Industries is a leading manufacturer of next generation security products based in New Windsor, NY. Polar designed and manufactures a patent pending 360° panoramic video camera for the security industry under the trademarked brand ZPAN, expanding the market presence of Polar’s ZNVR network video recorder products which were introduced in early 2004.

Business Strategy

Video surveillance is going through an historic analog - digital conversion, which opens opportunities for new companies to shake up legacy stakeholders.

- Polar’s strategy is to design and manufacture state of the art security systems, protect the designs with intellectual property and sell through both traditional security systems dealers and IT distribution channels.
- Polar’s success is in the growing customer base of systems integrators who now rely on us for their turnkey video surveillance systems and the Technology of the Year award from market researcher Frost & Sullivan.

Product/Service

Polar’s ZNVRs have been deployed in some of the toughest security installations for almost 3 years now with excellent results. The unique designs of the ZNVR give 30% better performance for video surveillance applications than the competition.. The ZPANs have been installed with customers since early 2006 and customer satisfaction is high. ZSOFT now completes the video surveillance system offering from Polar. All Polar’s products are available to OEM’s for those legacy companies who can’t transition fast enough to the digital security age.

Technology/Special Expertise

Polar has patents pending for ZPAN, ZNVR and copyrights for ZSOFT. Trademarks protect Polar’s logo and brands. Polar optimizes hardware designs for manufacturing and for reuse of common platforms.

Target Market

The target markets for Polar’s products are corporate and government security installations and we sell through systems integrators and distribution. Polar also has OEM customers for ZPAN and ZNVR/ ZSOFT.

Competition

The competition in this \$5 billion market is separated into two categories because Polar competes in 360°, IP surveillance software and network video recorders are combined. This is also Polar’s great strength as we can offer turnkey video surveillance packages to systems integrators. The competition in 360° is IPIX and they have 70% market share and Polar’s ZPAN beats them in price and performance; the competition for ZSOFT/ZNVR IP surveillance software is Milestone (16% share), JDS (11% share) and ONSSI (9% share) and Polar is significantly easier to install, use and upgrade.

Bank

Provident Bank
Newburgh, NY

Auditors

DeRienzo & Rossi, CPA

Law Firm

Corporate:
Christopher Basile; Duane Morris LLP
Patents:
Andrew T. Zidel; Lerner, David, Littenberg, Krumholz & Mentlik, LLP

Financials	Last Year	This Year	Three Years from now
Revenue	\$1,156,000	\$2,815,000	\$22,510,000
EBIT	\$0	\$0	\$13M



PrecisionCare Software, Inc.

243 Main Street
 Suite 270
 New Paltz, NY 12561

John Sheehan
 845.255.6097 x201
 jsheehan@precisioncare.com

Management

John Sheehan, CEO
 Christine Casillo, VP
 Marketing & Sales
 Salvatore Vitti, VP
 Technology
 Thomas Quinn, VP
 Business Development

Employees

10

Industry

Software and Services
 Healthcare

Finance

Financing Sought
 \$2.5M

Use of Funds

Marketing & Sales
 Product Development
 Working Capital

Current Investors

Angel Investor (\$220K)
 Ulster County
 Development Corp Loan
 (\$70K)

Financing to Date

\$290K

Company Description

PrecisionCare Software is a Software-as-a-Service (SaaS) developer of web-based electronic medical record solutions for Community-Based Healthcare providers with a focus on corporate compliance to ensure billing accountability and audit protection. PrecisionCare Software, founded in 2002, has successfully bootstrapped and raised angel capital to develop and sell its unique SaaS approach to over 60 customers throughout New York, Pennsylvania, and South Carolina.

Business Strategy

PrecisionCare seeks to raise \$2.5 million to fund a nationwide expansion leveraging National Human Service Organizations, Regional Partner Agencies, Industry Business Partners, Managed Care Providers and Direct Sales. Capital will also be used to develop new software and service components necessary to broaden PrecisionCare’s customer base across the entire Community-Based Healthcare marketplace.

Product/Service

PrecisionCare’s unique SaaS approach involves blending information technology expertise with best-of-care practical health care experience into a comprehensive electronic medical record solution. This enables Community Based Healthcare providers to focus on consumer care instead of documentation, significantly improve the quality of services they provide, drastically reduce operating costs, and avoid costly Medicaid and other audits from local, state, and federal regulators.

Technology/Special Expertise

PrecisionCare was first-to-market and is the established leader in community-based treatment medical record solutions throughout New York State. Our business model, strategy, developed technology and services, creates a protectable competitive advantage.

Target Market

There are over 150,000 Community-Based Treatment providers nationwide. The total market for electronic medical record solutions in this space is estimated to be \$1.2 billion nationwide and \$145 million in New York.

Competition

Very few cost effective SaaS solutions exist for Community-Based Treatment providers to comprehensively manage case records electronically and generate accurate billing information in full corporate compliance with mandated regulations. Key competitors include Foothold Technology, IMA Systems and Services and Anasazi Software. Customers have reported a number of factors in choosing PrecisionCare over the competition including Customer References and Quality of Service.

Bank

Citizens Bank

Auditors

Weinick Sanders Leventhal & Co., LLP

Law Firm

Jacobowitz & Gubits, LLP

Financials	Last Year	This Year	Three Years from now
Revenue	\$549,530	\$809,240	\$10,447,000
EBIT	\$32,396	\$135,000	\$3,572,000



RoomG03 Films

Mike Camoin—mike@videosforchange.com

1223 Peoples Avenue 518.312.4523 (o)

Troy, NY 12180 518.276.6380 (f)

www.grazingmissalbany.com 518.441.5300 (c)

Management Team

Mike Camoin, CEO,
Managing Member
Fred Siegel, CFO
(Outsourced) - NYC
Paul Farina, Marketing
Director
Sharon Wolin, Line
Producer

Cast & Crew

Cast: Jeff Fahey
(Lawnmower Man,
Grindhouse); Janine
Turner (Northern
Exposure);
David Keith (Officer and a
Gentleman).
Crew: Stephanie
Holbrook, Casting
Director; Phillip Timme,
Director of Photography;
Len X. Clayton,
Production Designer;
Russell Pflueger, 1st
Assistant Director;
Anthony Grocki, Assoc.
Producer/Editor
Industry Advisors: Bob
Hawk, ICI, NYC –
Sundance Film Festival;
Scott Stevens, Kodak
Entertainment
Imaging, NYC; Jeanine
Edmunds, Literary
Consultant

Industry

Movie / Entertainment
Industry

Financing Sought

Firm seeks \$1, 500,000 in
angel and venture capital
to produce an innovative
feature length motion
picture.

Use of Funds

Production of Feature Length Motion
Picture entitled "Grazing Miss Albany"
Delivered to Theatrical and Non-Theatrical
Markets Worldwide.

Company Description

RoomG03 Films is the feature filmmaking division of
Videos For Change, a Limited Liability Company
formed in 1992. Mike Camoin is the owner and
president of the company, which is a member of the
Rensselaer Polytechnic Institute Incubator Center in
Troy, NY, since 2002.

Over the next year, RoomG03 Films and Grazing, LLC
will produce the feature film Grazing Miss Albany, a
dramatic family comedy about American culture and
religion. The Company will be involved in the devel-
opment, production, and distribution of this \$1.75
million budgeted film. Grazing, LLC has entered into
a production services agreement with RoomG03
Films to produce the Film.

Business Strategy

The film will be screened by a team of industry
advisors before entering the marketplace. A NYC
marketing firm familiar with the entertainment
industry will handle publicity. Entry to the festival
circuit will begin at A-List Film Festivals: Cannes,
Sundance, Toronto, Berlin, etc. The film will be
distributed through a "sequential release" from
theatrical to non-theatrical (DVD, TV, etc.) and will
be represented at all major markets: Cannes,
MIPCOM, IFF, AFM by two distribution representa-
tives: (1) for North American territories and (2) for
all other foreign markets worldwide. An ancillary
product line of hats, mugs, buttons, t-shirts, magnets
are already developed and have found success in
local markets, soon to be available on-line.

Note: a veteran distributor predicts this film is likely
to garner mass appeal and has expressed interest in
representing.

Product/Service

There is a lack of quality family entertainment in the
low-budget filmmaking arena. Mike Camoin will
direct a personal and touching story about Patrick, the
troubled owner of a comfortable local diner and his
conflicted, yet devoted, girlfriend, Emma, who face
the challenges of a failing business and strained emo-
tional ties. The couple's future depends largely on the
actions of Patrick's estranged brother, Francis, a priest,
who seemingly holds the power of the diner's fate.
A timely, family drama with comedic undertones,

Grazing Miss Albany is where American culture and
religion cross.

Two live staged readings have taken place in the
Capital Region serving as an early test market
practice.

Technology/Special Expertise

The screenplay "Grazing Miss Albany," is
copyrighted with the US Copyright Office and
registered with the Writer's Guild of America.

Target market

Theatrical markets: 7 mini-major independent
distributors in North America, i.e. Focus Features,
Sony Picture Classics, etc. Theatrical release in
Foreign Territories Worldwide, e.g. Germany,
France, Japan, etc.
Non-Theatrical markets: DVD, Television, Cable,
Pay Cable, Internet, etc. Other Ancillary Markets.

Competition

Movies are a quality of life investment. Four factors
give Grazing Miss Albany an advantage over its
competition: (1) story (2) talent (3) approach to
marketplace and (4) timing.

Since 2004, the Federal Tax Incentive, see Tax Code
181, and the Empire State Tax Credit were created
to give production companies filming in New York
State a competitive advantage in the global market-
place.

Bank

State Employees Federal Credit Union (SEFCU)

Auditors

Fred Siegel, CPA – New York, NY

Law Firm

Innes Smolansky, Esq., Entertainment Attorney -
NYC
Spiak & Gray - NYC

Financing to Date

\$85,000 w/an additional \$65,000 in com-
mitments.

Five-Year Financial Projection Based on \$100K Investment (5.7% Equity)

	2005	2006	2007	2008	2009
	Actual	Actual			
Revenue (1500% return)	(\$100k)	\$40K	\$236K	\$1,164K	\$107K
EBITDA					

Sustainable Pharmaceuticals, Inc. d/b/a Systanix Inc.

3044 N. Triphammer Rd
Lansing, NY 14882

Steven Broadwater
607.257.9097
sjb42@cornell.edu

Management

Steven Broadwater, PhD,
Co-Founder
D. Tyler McQuade, PhD,
co-founder
Ankur Jain, MBA, partner

Employees

3

Industry

Pharmaceutical
Manufacturing
and Process
Intensification

Finance

Financing Sought
\$100,000 - \$750,000

Use of Funds

Prototype development
Process Development

Current Investors

None

Financing to Date

None

Company Description

Systanix, founded in 2005, is a process intensification company that will serve the pharmaceutical manufacturing industry. Combining advances in microreactor technology with streamlined synthetic routes to active pharmaceutical ingredients, both developed at Cornell University, Systanix will provide customers with a turn-key device capable of significantly reducing pharmaceutical manufacturing costs.

Business Strategy

Systanix will initially pursue customers in the field of generic pharmaceutical manufacturing. Systanix will select high-grossing drugs that are scheduled to come off patent within a short period of time and develop improved synthetic processes within its advanced microreactors. This will allow generics manufacturers to simply install a process and immediately reap the benefits.

Product/Service

Systanix has licensed technology developed in the McQuade Research Group at Cornell University that covers the design of an advanced microreactor. In addition, synthetic routes and proprietary catalysts have been developed for use within the microreactor. The combination of an advanced reactor and a tailor-made process will present Systanix with a significant competitive advantage in the pharmaceutical sector.

Technology/Special Expertise

Systanix has exclusively licensed rights to an advanced microreactor system from the Cornell Center for Technology, Enterprise, and Commercialization.

Any additional advances achieved within the McQuade Research Group will also be licensed.

Target Market

Systanix will initially target the generic pharmaceutical manufacturing market. After establishing a reputation as a leader in the field of process intensification, Systanix will engage branded pharmaceutical companies for outsourcing their process development needs.

Competition

There are two major competitors to Systanix in the microreactor market: Cellular Process Chemistry (CPC) and Velocys. Both companies are based off of technology that differs from Systanix. Both companies provide customers with microreactors only; they do not provide the methodology necessary to obtain the benefits associated with microreactor technology.

Law Firm

Jaeckle, Fleischmann & Mugel LLP

Financials	Last Year	This Year	Three Years from now
Revenue	\$0	\$0	\$10,500,500
EBIT	\$0	\$0	-\$550,000

Synceros, Inc.

127 West State Street
Ithaca, NY 14850

Olivier Zanen
607.273.3288
poz2@synceros.com

Management

Olivier Zanen
Founder, CTO

Bangjun Lei, PhD
Co-founder

Employees

2

Industry

Healthcare Products,
Medical Instrumentation

Finance

Financing Sought
\$1M

Use of Funds

Product development
Product manufacturing
Marketing
Working capital

Current Investors

Private investors

Financing to Date

\$0.4M

Company Description

Synceros targets the large, significant market of Minimal Access Surgery (MAS). Today, surgeons performing MAS with conventional 2D systems lack depth perception. Our innovative 3D imaging system restores depth perception in a package designed to ease the transition from 2D to 3D imaging for hospitals and surgeons. Synceros built a proof of concept prototype that validates the merits of its patented optics and proprietary software solutions. Synceros has obtained initial support from two leading teaching hospitals in New York City and is seeking additional capital to fund product development and 510k FDA approval.

Business Strategy

Synceros will leverage its unique IP position to sustain itself as an innovator of medical 3D imagers for MAS and develop a network of distribution partnerships to extend the company's reach into its target markets. Initially, we will finalize the product concept in the non-FDA veterinary MAS market, followed by the human MAS market after obtaining FDA approval.

Product/Service

By restoring depth perception, our 3D imaging system makes MAS procedures easier to learn, safer, and faster to perform. It seamlessly complements existing operating room equipment, rather than replacing it. Our turnkey 3D system can be offered at a price point in line with conventional 2D systems. Ongoing profit will be made with recurrent sales of the single use 3D adaptors. Another benefit of using our system is shorter post-surgery recovery periods, saving costs for patients and insurance companies as further incentive.

Technology/Special Expertise

Synceros' single camera 3D imaging system combines patented optics and advanced imaging software, resulting in extremely cost effective, technically superior methods for generating 3D imaging. Synceros has exclusive rights to key patents in our target markets. In the field of 3D optics, 4 patents have been issued and one other is pending. In the field of machine vision, 2 patents have been issued.

Target Market

While our technology has been verified with potential clients in 4 other attractive markets, our focus is on 3D imaging systems for the MAS market. Worldwide, the MAS market demands 12,000-14,000 new complete imaging systems annually. In the US alone, an estimated 5,000 general surgeons each perform about 300-500 MAS procedures annually. The Synceros system has both multi-use and single-use components, providing an on-going revenue stream.

Competition

The Synceros product will significantly outperform all 2D and newly emerging 3D competition. The 3D competition is based either on cumbersome, heavy 3D goggles or on technology with shortcomings unacceptable to most surgeons. Our system will retail below current 3D system price points, and expand the MAS market by addressing the inherent limitations of currently available 2D and 3D systems.

Bank

M&T Bank, Ithaca, NY

Auditors

Margolis Shapiro & Co., Boston, MA

Law Firm

Horner Law Office, Ithaca, NY

Financials	Last Year	This Year	Three Years from now
Revenue	\$6,810	\$13,610	\$5,496,000
EBIT	\$55,495	(\$33,050)	\$2,227,750

Tetragenetics, Inc.

95 Brown Rd. Box 1010
Ithaca, NY 14850
www.tetragenetics.com

John Reilly
607-257-1199
jreilly@tetragenetics.com

Management

Dr. William Gordon,
CEO/Pres.
R. Douglas Kahn,
Chairman
Dr. Theodore Clark, CSO
Dr. Martin Gorovksy,
Board Member
John Reilly, Director,
Business Development

Employees

2

Industry

Biotechnology/Vaccine

Finance

Financing Sought
\$2M

Use of Funds

Working capital
Build management team
Flu Vaccine R&D
Expression kit validation

Current Investors

Private Investors

Financing to Date

\$100,000 angel;
\$300,000 grant

Company Description

"Tetragenetics" (or the "Company") is a vaccine discovery and development company. We seek to become the world-leader in the commercial application of the TetraExpress™ production system by developing products and services for the vaccine market.

Business Strategy

Our business model, based on revenues derived from state and federal grants, vaccine licensing, custom protein expression work, and retail sales of expression kits, together with funding of selective R&D projects by strategic partners, puts us in a position to aggressively execute development programs with minimal impact on our financial reserves. We seek to bring vaccines for large unmet medical needs into clinical trials where we will partner/license them with/to leading biopharmaceutical companies.

Product/Service

TetraExpress™ refers to a suite of technologies that encompasses both over-expression and novel methods of purification of genetically engineered membrane and secretory proteins.

Technology/Special Expertise

Our technology platform is Tetrahymena thermophila, a single-celled organism with unique biological properties that allow high-level expression of genetically engineered (recombinant) proteins at extremely low cost. Because of its numerous cilia, Tetrahymena has a vast surface area, and devotes a large part of its metabolism towards membrane protein production. This feature is unique to ciliates, and distinguishes Tetrahymena from all other systems currently employed for the commercial

manufacture of recombinant vaccines and biotherapeutics. Importantly, TetraExpress™ can be used to mimic enveloped viruses, and thus has direct application to the production of influenza vaccines, where low production costs and low safety risks, together with rapid scale-up are ideally suited to the challenges of newly emerging flu strains including life-threatening pandemic virus variants.

Target Market

Influenza vaccine (current annual sales of > \$1 B for the sector as a whole). Approximately 5 to 20% of Americans get the flu each year, leading to 36,000 deaths and 200,000 hospitalizations annually. Datamonitor projects that the influenza market will reach \$3.7B by 2010.

Competition

There are approximately 11 other companies seeking to bring a flu vaccine to market. All are at varying stages of development and commercialization. FluViral (GSK) and InFluVac (Solvay) are the first to be launched in 2006.

Bank

Tompkins Trust Company

Auditors

Scirabba & Walker

Law Firm

Harris Beach
Goodwin Procter

Financials	Last Year	This Year	Three Years from now
Revenue	\$(51,437)	\$995,000	\$30,000,000
EBIT	\$0	\$(377,000)	\$8,000,000

Vaspian

461 Ellicott Street
Buffalo, NY 14203

Perry A. Ciambella
716-961-9525
pciambella@vaspian.com

Management Team

Brian Hurley, CEO
Perry Ciambella, President
Maggie Sommers, Exec. VP
Randy Clark, GM Buffalo
Greg Schreiber, VP Prd. Dev.
Tim Kearney, VP Engineering
Mike Bagar, Network Ops.
Darren Ascone, VP Ops

Employees

18

Industry

Software Subscriptions—
Telecommunications
Service Provider

Finance

Financing Sought:
\$3.5 Million

Use of Funds

- Sales & Marketing development
- Working Capital
- Hardware and Software

Financing to Date

Friends, Family and
Accredited Investors

Company Description

Vaspian LLC was founded in 2004, went cash flow positive in July 2005, has 18 employees and an excellent team of managers. Vaspian stands at the nexus of the converging Telecom and Software industries. The success of Sales force.com is a harbinger of what is to come and why Vaspian can be the next Microsoft.

Business Strategy

Vaspian's strategy is to follow the success of our direct sales force with a focus on specific vertical markets: Real estate, Government Agencies, Trucking, Educational Institutions, Call Centers, Health Care facilities, Manufacturers, Distributors, etc. and use those as a strong referral base. Alternative Channel development includes an agreement with a national network of 3,000 IT service shops.

Product/Service

Vaspian focuses on satisfying a critical need to every business—its phone system. We don't replace phone systems; we eliminate the need for them:

- we host a software-based phone system solution in our network,
- tying our customers in with a point to point T1;
- we provide businesses with real-time power and control over their communication system,
- help them run their businesses more efficiently,
- and provide service and savings via the network that were previously impossible.

This platform can easily provide many other hosted software applications to our captive subscriber base.

Management/Special Expertise

Vaspian has assembled an excellent array of talent in its management team.

Brian Hurley	Randy Clark
Perry Ciambella	Greg Schreiber
Timothy Kearney	Darren Ascone

Target Market

Currently Vaspian has 1,600 seats with 85 customers, \$2MM run rate, 0 Churn and profitable in its 1st Yr.

Vaspian is targeting Small to Medium Size Businesses (SMB) with 10 or more lines.

According to the most recent census data there are 19 Million SMBs in North America 3.9 Million of which are top candidates for X-Tone. That segment alone represents over \$27 Billion in non-recurring potential and \$40 Billion in recurring revenue/year. With proper funding, Vaspian can easily corner the converging business telecom/software market.

Competition

Vaspian's chief competition comes from premise based phone system solutions partnered with a host of ILEC or CLEC, IT company and broadband providers. We haven't lost against that solution since we are simpler, more powerful, less expensive and more reliable; we better fit customer needs and provide superior service.

Hosted VoIP solutions: BroadSoft, Sylantro, Cisco Call Manager or open source based solutions cannot compete (more \$, poor service) for the under 50 seat customer. This is not only demonstrated by comparative product analysis—Covad, CBeyond, 8X8, have all made admissions or actions recently that confirm this.

Bank

HSBC

Law Firm

Phillips Lytle, Buffalo

Financial Projections

Projected* Revenue & EBITDA (\$1,000,000's) (est.)

Assumes no further funding from a second or subsequent round.

This Document contains forward looking information.

Wireless Grids Corporation

2-120 Center for
Science & Technology
Syracuse, NY 13244

Dr. Lee McKnight
1-315-278-4392
lee.mcknight@wirelessgrids.us

Management

Dr. Lee McKnight,
Chairman
Charlie Rabie, CEO
Michael Orshan, VP
Business Development
Andrew Kennedy, VP
Engineering

Employees

7

Industry

Information Technology

Finance

Financing Sought
\$8M

Use of Funds

Product Development
Sales
Marketing

Current Investors

Private Investors
Liberty Partners

Financing to Date
\$500,000

Company Description

WGC is driving the evolution and emergence of a new de facto industry standard to make it easy and secure to share content, software and hardware resources across disparate devices such as PC's, cell phones, plasma TV's, network routers, printers and cameras.

Over \$1 million has thus far been allocated to this work from the NSF and Industry/Cross-University collaboration with companies including Cisco, BT, Novell, and Hitachi.

Wireless Grids Corporation was founded with the objective of commercializing technology from the cross-university NSF-funded R&D project. The exclusive license to the related intellectual property portfolio was arranged with Syracuse, Tufts, and Boston Universities, and a first contract was signed in 2005 with a major European broadband provider for the development of an initial Home Wireless Grid Proof of Concept. Shortly thereafter, the first successful public trials were completed at the Boston Museum of Science Summer Institute.

Business Strategy

The Wireless Grids Corporation (WGC) mission is to make it easy and secure to share content, hardware and software across popular home and personal appliances such as PCs, cell phones, network routers, plasma TV's, cameras and printers. WGC uses a variety of well-established data transport methods and offers the next generation application that connects disparate devices so that home digitized information can be shared seamlessly.

WGC's solution offers the opportunity for home network owners to share photos, documents, music, movies, printers, DVDs, displays, sound mixers, security devices, and other digitized information. This highly versatile solution is designed to be highly scalable. The software is extremely lightweight, platform-agnostic (Linux, Windows, Mac, etc.), and offers a wide range of compelling applications that can be delivered to consumers.

WGC has a two prong business strategy to proliferate its software: firstly, it will build applications for existing home network providers such as ISP's cable and carrier companies, so they can serve as a WGC distribution channel. The value proposition to these providers is that WGC offers compelling applications for the home digitized market on devices that they can't access today. Recent surveys indicate that customers would pay more for these value-added

applications. The second WGC distribution method would be to develop applications that could be directly downloaded by consumers at no cost. These applications may include sharing physical devices such as printers at home, or sharing photos or music between PC's or cell phones. This strategy serves to establish WGC as the experts in easy and secure sharing of content, software and hardware and will have the effect of dramatically increase demand.

Product/Service

WGC offers a leading edge architecture and toolkit to develop compelling applications that share content hardware and software securely.

WGC offers customers the ability to rapidly build their own applications or it can deliver the applications for them using this toolkit.

The underpinning technology functions across a range of industry standards, RF bands and wireless languages. From Wi-Fi to Wimax to Zigbee to 3G – from Mobile Service to Fixed Broadband offerings – Wireless Grids provides a secure sharing platform that allows all enabled devices to communicate seamlessly with each other.

Technology/Special Expertise

WGC has unique technology and deep service expertise to create applications that allow users to share content, hardware and software. Its technology is simple and secure to use.

Target Market

Home networking is one of the fastest growing trends in broadband today. According to Parks Associates, more than half of broadband households currently have a home network installed, and as many as 40 million U.S. households are projected to have home networks by 2007. The target market is large home network providers including ISP's and carriers in North America, EMEA and Asia Pacific.
Competition

There are a number of point competitors including Microsoft who offer part of the solution in more complex and difficult ways to use. Pure Networks makes similar claims but don't adhere to industry standards and are electing to sell their technology directly rather than through channels.

Financials	Last Year	This Year	Three Years from now
Revenue	\$666,666	\$1,666,666	\$3,666,666
EBIT	\$000	\$000	\$000

WizWak Mobile Solutions, LLC

251 53rd Street
Brooklyn, NY, 11220

William Stutzman
203-668-4850
bstutzman@wizwak.com

Management

Roland Dib,
CEO/Founder;
Bill Stutzman, President;
Doug Vunic, CTO;
Gregg Dearth, CMO;
George Dib, VP
Production

Employees

5

Industry

Description of the
industry

Finance

Financing Sought
\$5 million

Use of Funds

Working Capital,
Technology,
Production/Development,
Sales/Marketing

Current Investors

Roland Dib

Financing to Date

None

Company Description

Wizwak Mobile Solutions, founded in September of 2005 has a patent pending M-server application that allows for the creation of custom video and text messages delivered to mobile phones, email or IM using WAP, MMS or 3G technology. Our technology will provide a platform for companies to move video content to mobile phones or generate video content from photo and text databases. Industries that we have targeted include real estate, entertainment, and print and web classified publishers.

Business Strategy

As a first mover we are concentrating our business strategy on 3 segments that have existing sales channels that we can enter easily, with relatively short time to market. These are real estate, Broadway trailers, and web/broadband video conversion to mobile. Test marketing is already in place for mobile real estate solution with East Coast launch planned for June 18th. In the web/broadband market resellers are being sought for the conversion of broadband video to mobile with a potential deal to close in 30 days. A final area we are working on is the build out of Broadway Show, 30 second sampler to be marketed in NY in conjunction with the local theaters. It is our intention to move quickly into areas that we can grow revenues while proving the viability of the marketplace.

Product/Service

WizWak Mobile Solutions has two product lines. A white label solution that can be integrated into systems that are currently delivering video in other formats that allows for transfer of that video to mobile phones. This market we anticipate will provide a solid base of revenues with large upfront fees and monthly maintenance fees. It will be sold primarily via resellers that are in the broadband marketplace. The second product line will consist of specific B2B ASP solutions targeted to specific industry segments such as real estate. For example, we will provide a product that allows realtors to offer instant home video tours on the cellphone created from still photos and an MLS directory

database. The system can either be implemented directly or on a one off basis.

Technology/Special Expertise

The patent pending WizWak M-server involves a sequence process that the server goes through to fulfill an order coming from a cell phone including receiving cell phone message input, processing it by selecting requested info from a database server, creating a one off custom output and dynamically generate a video or message as output to send to a cell phone, email or IM account. Additionally, proprietary code was developed that allows the M-server to manage the communication between the other servers such as the video data base server, the video rendering server, e-commerce server, and the stats server.

Target Market

Primary markets we have identified that are appropriate for using the WizWak M-server are 76,000 real estate brokerage offices with 1.2 million agents for custom video home tours on the phone, 13,000 movie studios and theatrical organizations for custom trailers with show-times, and 8,000 newspapers for print to mobile video classifieds.

Competition

There is limited number of competitors in our B2B custom video solutions segment. Our focus on developing business applications that are supported with marketing dollars or directly paid for on a per lead basis will differentiate us in the marketplace. Positioning us for the movement of mobile from an entertainment device to a service device in a similar manner that the web has developed.

Bank

Chase Bank, Brooklyn, NY

Auditors

Seesa, Fisher, & Fineli, Brooklyn, NY

Law Firm

Zraic, Nahas & Rich, Brooklyn, NY

Financials	Last Year	This Year	Three Years from now
Revenue	\$0	\$645k	\$17mm
EBIT	(\$200k)	(\$775mm)	\$6.3mm

